BR112014008529A2 - il-6 humanizado e receptor de il-6 - Google Patents

il-6 humanizado e receptor de il-6

Info

Publication number
BR112014008529A2
BR112014008529A2 BR112014008529A BR112014008529A BR112014008529A2 BR 112014008529 A2 BR112014008529 A2 BR 112014008529A2 BR 112014008529 A BR112014008529 A BR 112014008529A BR 112014008529 A BR112014008529 A BR 112014008529A BR 112014008529 A2 BR112014008529 A2 BR 112014008529A2
Authority
BR
Brazil
Prior art keywords
mouse
mice
receptor
human
endogenous
Prior art date
Application number
BR112014008529A
Other languages
English (en)
Portuguese (pt)
Inventor
J Murphy Andrew
T Dore Anthony Jr
Wang Li-Hsien
Stevens Sean
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112014008529A2 publication Critical patent/BR112014008529A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014008529A 2011-10-28 2012-10-29 il-6 humanizado e receptor de il-6 BR112014008529A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552900P 2011-10-28 2011-10-28
US201161556579P 2011-11-07 2011-11-07
PCT/US2012/062379 WO2013063556A1 (en) 2011-10-28 2012-10-29 Humanized il-6 and il-6 receptor

Publications (1)

Publication Number Publication Date
BR112014008529A2 true BR112014008529A2 (pt) 2017-04-18

Family

ID=47295138

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008529A BR112014008529A2 (pt) 2011-10-28 2012-10-29 il-6 humanizado e receptor de il-6

Country Status (27)

Country Link
US (10) US8878001B2 (enExample)
EP (2) EP2818478B1 (enExample)
JP (2) JP6120451B2 (enExample)
KR (2) KR102084927B1 (enExample)
CN (2) CN108866101A (enExample)
AU (1) AU2015207889B2 (enExample)
BR (1) BR112014008529A2 (enExample)
CA (1) CA2853731C (enExample)
CY (2) CY1116614T1 (enExample)
DK (2) DK2663575T3 (enExample)
ES (2) ES2624605T3 (enExample)
HR (2) HRP20141192T1 (enExample)
HU (1) HUE033400T2 (enExample)
IL (4) IL231896B (enExample)
IN (1) IN2014CN03920A (enExample)
LT (1) LT2818478T (enExample)
MX (1) MX358390B (enExample)
MY (2) MY172726A (enExample)
PL (2) PL2663575T3 (enExample)
PT (2) PT2818478T (enExample)
RS (2) RS53683B1 (enExample)
RU (2) RU2751240C2 (enExample)
SG (3) SG10202100485XA (enExample)
SI (2) SI2663575T1 (enExample)
SM (2) SMT201700222T1 (enExample)
WO (1) WO2013063556A1 (enExample)
ZA (1) ZA201402635B (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3417701B1 (en) 2009-10-06 2021-12-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
RU2577978C2 (ru) 2011-02-15 2016-03-20 Ридженерон Фармасьютикалз, Инк. Гуманизированные m-csf мыши
RU2751240C2 (ru) 2011-10-28 2021-07-12 Регенерон Фармасьютикалс, Инк. Гуманизированные il-6 и рецептор il-6
US20130261016A1 (en) * 2012-03-28 2013-10-03 Meso Scale Technologies, Llc Diagnostic methods for inflammatory disorders
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
NZ746089A (en) 2012-09-07 2020-05-29 Institute For Res In Biomedicine Irb Genetically modified non-human animals and methods of use thereof
JP6282591B2 (ja) * 2012-09-13 2018-02-21 中外製薬株式会社 遺伝子ノックイン非ヒト動物
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
JP6444321B2 (ja) 2013-02-22 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化主要組織適合性遺伝子複合体を発現するマウス
GB2513884B (en) 2013-05-08 2015-06-17 Univ Bristol Method and apparatus for producing an acoustic field
SMT202500280T1 (it) 2013-09-23 2025-09-12 Regeneron Pharma Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale
TR201904342T4 (tr) 2013-10-15 2019-05-21 Regeneron Pharma Hümani̇ze il-15 hayvanlar
EP3071024B1 (en) * 2013-11-19 2018-09-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
EP3430898A1 (en) * 2013-11-19 2019-01-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
US9612658B2 (en) 2014-01-07 2017-04-04 Ultrahaptics Ip Ltd Method and apparatus for providing tactile sensations
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
SMT202000332T1 (it) 2014-04-08 2020-07-08 Regeneron Pharma Animali non umani aventi recettori fc-gamma umanizzati
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
NO2785538T3 (enExample) 2014-05-07 2018-08-04
KR102821645B1 (ko) 2014-05-19 2025-06-19 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
BR112016026245A2 (pt) 2014-05-30 2018-02-20 Regeneron Pharma ?roedor, e, métodos para fazer um roedor humanizado, para fazer um camundongo com dpp4 humanizado, para fazer um roedor transgênico humanizado e para determinar a eficácia terapêutica in vivo de um antagonista da dpp4 específica para humanos no roedor?
DK3157956T3 (da) 2014-06-19 2020-04-27 Regeneron Pharma Ikke-humane dyr med et humaniseret gen med programmeret celledød 1
GB2530036A (en) 2014-09-09 2016-03-16 Ultrahaptics Ltd Method and apparatus for modulating haptic feedback
BR112017010793A2 (pt) 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
ES2969389T3 (es) * 2014-12-05 2024-05-17 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado
EP4399969A3 (en) 2014-12-09 2024-10-30 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
EP3537265B1 (en) 2015-02-20 2021-09-29 Ultrahaptics Ip Ltd Perceptions in a haptic system
CN107534810B (zh) 2015-02-20 2019-12-20 超级触觉资讯处理有限公司 用于提供改进的触觉反馈的方法
AU2016246698B2 (en) 2015-04-06 2022-06-02 Regeneron Pharmaceuticals, Inc. Humanized T cell mediated immune responses in non-human animals
SG10202103445QA (en) 2015-04-13 2021-05-28 Regeneron Pharma Humanized sirpa-il15 knockin mice and methods of use thereof
US10818162B2 (en) 2015-07-16 2020-10-27 Ultrahaptics Ip Ltd Calibration techniques in haptic systems
PT3376857T (pt) 2015-11-20 2021-05-27 Regeneron Pharma Animais não humanos com um gene humanizado 3 de ativação de linfócitos
MX2018007061A (es) 2015-12-08 2018-08-15 Regeneron Pharma Composiciones y metodos para enzimas de internalizacion.
US11189140B2 (en) 2016-01-05 2021-11-30 Ultrahaptics Ip Ltd Calibration and detection techniques in haptic systems
US10582702B2 (en) 2016-02-04 2020-03-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered ANGPTL8 gene
CA3014645C (en) 2016-02-29 2022-10-25 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
IL263160B2 (en) 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
US10531212B2 (en) 2016-06-17 2020-01-07 Ultrahaptics Ip Ltd. Acoustic transducers in haptic systems
US10268275B2 (en) 2016-08-03 2019-04-23 Ultrahaptics Ip Ltd Three-dimensional perceptions in haptic systems
US10755538B2 (en) 2016-08-09 2020-08-25 Ultrahaptics ilP LTD Metamaterials and acoustic lenses in haptic systems
CN107815467B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
US10943578B2 (en) 2016-12-13 2021-03-09 Ultrahaptics Ip Ltd Driving techniques for phased-array systems
US10497358B2 (en) 2016-12-23 2019-12-03 Ultrahaptics Ip Ltd Transducer driver
CN108467873B (zh) 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
CN108588126B (zh) 2017-03-31 2020-04-10 北京百奥赛图基因生物技术有限公司 Cd47基因人源化改造动物模型的制备方法及应用
WO2018177441A1 (en) * 2017-03-31 2018-10-04 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα
EP3585162B1 (en) 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
US11531395B2 (en) 2017-11-26 2022-12-20 Ultrahaptics Ip Ltd Haptic effects from focused acoustic fields
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
US11704983B2 (en) 2017-12-22 2023-07-18 Ultrahaptics Ip Ltd Minimizing unwanted responses in haptic systems
US11360546B2 (en) 2017-12-22 2022-06-14 Ultrahaptics Ip Ltd Tracking in haptic systems
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
IL278402B2 (en) 2018-05-02 2025-10-01 Ultrahaptics Ip Ltd Blocking element for acoustic transmission with improved efficiency
HUE067361T2 (hu) * 2018-07-16 2024-10-28 Regeneron Pharma Ditra betegség rágcsáló modelljei és alkalmazásaik
US11098951B2 (en) 2018-09-09 2021-08-24 Ultrahaptics Ip Ltd Ultrasonic-assisted liquid manipulation
US11378997B2 (en) 2018-10-12 2022-07-05 Ultrahaptics Ip Ltd Variable phase and frequency pulse-width modulation technique
WO2020125639A1 (en) * 2018-12-17 2020-06-25 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric genes
US12373033B2 (en) 2019-01-04 2025-07-29 Ultrahaptics Ip Ltd Mid-air haptic textures
WO2020141330A2 (en) 2019-01-04 2020-07-09 Ultrahaptics Ip Ltd Mid-air haptic textures
CN111218425B (zh) * 2019-01-17 2022-02-08 百奥赛图(北京)医药科技股份有限公司 人源化转基因动物
AU2020253532B2 (en) 2019-04-04 2024-06-20 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
US11842517B2 (en) 2019-04-12 2023-12-12 Ultrahaptics Ip Ltd Using iterative 3D-model fitting for domain adaptation of a hand-pose-estimation neural network
JP7699749B2 (ja) * 2019-05-27 2025-06-30 株式会社トランスジェニックグループ エクソンヒト化マウス
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
SG11202111256XA (en) 2019-06-07 2021-11-29 Regeneron Pharma Non-human animals comprising a humanized albumin locus
US11374586B2 (en) 2019-10-13 2022-06-28 Ultraleap Limited Reducing harmonic distortion by dithering
US11553295B2 (en) 2019-10-13 2023-01-10 Ultraleap Limited Dynamic capping with virtual microphones
US11169610B2 (en) 2019-11-08 2021-11-09 Ultraleap Limited Tracking techniques in haptic systems
CN111304246B (zh) * 2019-12-17 2021-05-04 百奥赛图江苏基因生物技术有限公司 一种人源化细胞因子动物模型、制备方法及应用
US11715453B2 (en) 2019-12-25 2023-08-01 Ultraleap Limited Acoustic transducer structures
JP2023511626A (ja) * 2020-01-28 2023-03-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｐｎｐｌａ３遺伝子座を含む非ヒト動物および使用方法
JP7765403B2 (ja) 2020-04-21 2025-11-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｃｘｃｌ１３遺伝子を有する非ヒト動物
US11816267B2 (en) 2020-06-23 2023-11-14 Ultraleap Limited Features of airborne ultrasonic fields
US11886639B2 (en) 2020-09-17 2024-01-30 Ultraleap Limited Ultrahapticons
IL307238A (en) 2021-03-31 2023-11-01 Regeneron Pharma Transgenic mice containing human components of the cellular immune system with an enhanced diversity of the TCRB repertoire
WO2024073679A1 (en) 2022-09-29 2024-04-04 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2025250495A1 (en) 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012025A1 (en) * 1994-10-14 1996-04-25 Basf Aktiengesellschaft TRANSGENIC NONHUMAN ANIMAL HAVING FUNCTIONALLY DISRUPTED INTERLEUKIN-1β CONVERTING ENZYME GENE
WO1996012503A1 (en) 1994-10-21 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Remedy for diseases caused by il-6 production
US20030082721A1 (en) * 2001-01-17 2003-05-01 Tai-Jay Chang Transgenic animals expressing androgen receptor complex-associated protein
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
US7759541B2 (en) * 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
WO2008027986A2 (en) * 2006-09-01 2008-03-06 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
FR2942218A1 (fr) 2009-02-13 2010-08-20 Eurocave Sa Appareil de service au verre d'un liquide, notamment de vin
EP3417701B1 (en) 2009-10-06 2021-12-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
EP3336102A3 (en) * 2009-12-21 2018-08-01 Regeneron Pharmaceuticals, Inc. Humanized fc gamma r mice
RU2577978C2 (ru) 2011-02-15 2016-03-20 Ридженерон Фармасьютикалз, Инк. Гуманизированные m-csf мыши
CN110680920A (zh) * 2011-09-30 2020-01-14 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
RU2751240C2 (ru) 2011-10-28 2021-07-12 Регенерон Фармасьютикалс, Инк. Гуманизированные il-6 и рецептор il-6
KR102295746B1 (ko) 2011-10-28 2021-09-01 리제너론 파아마슈티컬스, 인크. 유전자 변형된 주요 조직적합성 복합체 마우스
SG10201510056SA (en) 2011-10-28 2016-01-28 Regeneron Pharma Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules

Also Published As

Publication number Publication date
US20200008407A1 (en) 2020-01-09
IL264508B (en) 2019-12-31
CN108866101A (zh) 2018-11-23
US11102962B2 (en) 2021-08-31
US20160278352A1 (en) 2016-09-29
US20130117873A1 (en) 2013-05-09
DK2663575T3 (en) 2014-12-15
HUE033400T2 (en) 2017-12-28
HRP20141192T1 (hr) 2015-02-13
PT2818478T (pt) 2017-05-12
US8878001B2 (en) 2014-11-04
HK1205135A1 (en) 2015-12-11
JP6120451B2 (ja) 2017-04-26
HRP20170656T1 (hr) 2017-06-30
US9622460B2 (en) 2017-04-18
US20220053742A1 (en) 2022-02-24
IL243665B (en) 2018-02-28
WO2013063556A8 (en) 2014-04-17
IL231896B (en) 2018-02-28
SMT201700222T1 (it) 2017-07-18
SG11201400945UA (en) 2014-04-28
US20250287931A1 (en) 2025-09-18
RU2751240C2 (ru) 2021-07-12
US20180271071A1 (en) 2018-09-27
US20170055506A1 (en) 2017-03-02
US9078418B2 (en) 2015-07-14
KR102234632B1 (ko) 2021-04-02
AU2015207889B2 (en) 2017-02-23
EP2818478B1 (en) 2017-02-01
SG10202100485XA (en) 2021-02-25
IN2014CN03920A (enExample) 2015-09-04
US10004211B2 (en) 2018-06-26
RU2017129763A (ru) 2019-02-05
IL231896A0 (en) 2014-05-28
CY1116614T1 (el) 2017-03-15
CA2853731C (en) 2021-05-18
MY172726A (en) 2019-12-11
RS53683B1 (sr) 2015-04-30
EP2818478A1 (en) 2014-12-31
RS55949B1 (sr) 2017-09-29
SI2818478T1 (sl) 2017-07-31
MX2014004900A (es) 2014-08-26
LT2818478T (lt) 2017-06-12
SI2663575T1 (sl) 2015-01-30
MY186903A (en) 2021-08-26
US12239111B2 (en) 2025-03-04
RU2017129763A3 (enExample) 2020-12-18
DK2818478T3 (en) 2017-05-22
PL2818478T3 (pl) 2017-09-29
WO2013063556A4 (en) 2013-06-20
US20150013023A1 (en) 2015-01-08
WO2013063556A1 (en) 2013-05-02
AU2015207889A1 (en) 2015-08-20
IL243666B (en) 2019-02-28
EP2663575B1 (en) 2014-10-01
US20150013022A1 (en) 2015-01-08
ZA201402635B (en) 2015-09-30
EP2663575A1 (en) 2013-11-20
PL2663575T3 (pl) 2015-03-31
US9125386B2 (en) 2015-09-08
US10433528B2 (en) 2019-10-08
CN104039821A (zh) 2014-09-10
SG10201600965YA (en) 2016-03-30
HK1190408A1 (en) 2014-07-04
NZ623145A (en) 2015-09-25
KR20200024949A (ko) 2020-03-09
US20150272092A1 (en) 2015-10-01
CY1118952T1 (el) 2018-01-10
KR102084927B1 (ko) 2020-03-06
PT2663575E (pt) 2014-12-05
IL243665A0 (en) 2016-03-31
IL243666A0 (en) 2016-03-31
ES2624605T3 (es) 2017-07-17
CA2853731A1 (en) 2013-05-02
MX358390B (es) 2018-08-17
NZ709432A (en) 2015-12-24
JP2014532416A (ja) 2014-12-08
US9392777B2 (en) 2016-07-19
KR20140091024A (ko) 2014-07-18
RU2014121324A (ru) 2015-12-10
SMT201400187B (it) 2015-01-15
ES2525368T3 (es) 2014-12-23
JP2017035115A (ja) 2017-02-16
IL264508A (en) 2019-02-28
RU2634417C2 (ru) 2017-10-26

Similar Documents

Publication Publication Date Title
BR112014008529A2 (pt) il-6 humanizado e receptor de il-6
EA201491470A1 (ru) Композиции фактора viii и способы получения и использования подобных
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
BR112013033671A2 (pt) composições de polipeptídeo de fusão fc livre de arginina e métodos de uso
BR112013027229A2 (pt) composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas
MY175708A (en) Dna antibody constructs and method of using same
BR112014029066A2 (pt) composição para a redução das sensações de trpa1 e trpv1
BR112016005526A2 (pt) anticorpos receptores de fator de crescimento anti-epidérmido modificado e métodos de uso dos mesmos
BR112015027528A2 (pt) polipeptídeo, combinação farmacêutica, métodos de tratamento de um distúrbio metabólico e de obesidade, uso de um polipeptídeo ou de uma combinação farmacêutica, molécula de ácido nucleico, vetor de expressão, e, célula hospedeira
BR112016001114A2 (pt) membros da família tnf direcionados modificados
BR112014017165A8 (pt) polipeptídeos de fator quimérico viii e seus usos
CL2008001674A1 (es) Dominio variable simple (dab) de inmunoglobulina anti-fator de crecimiento endotlial vascular (vegf); acido nucleoico que lo codifica; vector y celula huesped; metodo de produccion; antagonosta de vegf que comprende el dab; composiicon que comprende al antagonista; y uso del antagonista para prepara un medicamento.
BR112014014913A2 (pt) mutante prongf e método de preparação de uma beta-ngf humana biologicamente ativa
MX2013008702A (es) Composiciones que contienen anticuerpos glicosilados y sus usos.
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
BR112015027757A2 (pt) elastômeros parcialmente fluorados e métodos para a produção e uso dos mesmos
CL2012003077A1 (es) Polipeptido que comprende el decimo dominio de fibronectina tipo iii (10fn3), en donde el dominio 10fn3 se une al dominio 1 o 2 de seroalbumina humana, y donde la vida media del suero del polipéptido en presencia de seroalbumina es al menos 5 veces mayor que en su ausencia; acido nucleico que lo codifica; vector que lo comprende; celula hospedera que lo expresa; composición que lo comprende; y su uso para tratar la diabetes.
BR112015008612A2 (pt) métodos de tratamento utilizando adenovirus
EA201491676A1 (ru) Партии рекомбинантного аденовируса с измененными концевыми областями
BR112018011838A2 (pt) terapia gênica para distúrbios oculares
MX391136B (es) FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
EA201590359A1 (ru) Лечение ревматоидного артрита
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements